Mitochondrial-Linked De Novo Pyrimidine Biosynthesis Dictates Human T-Cell Proliferation but Not Expression of Effector Molecules

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

T-cell activation upon antigen stimulation is essential for the continuation of the adaptive immune response. Impairment of mitochondrial oxidative phosphorylation is a well-known disruptor of T-cell activation. Dihydroorotate dehydrogenase (DHODH) is a component of the de novo synthesis of pyrimidines, the activity of which depends on functional oxidative phosphorylation. Under circumstances of an inhibited oxidative phosphorylation, DHODH becomes rate-limiting. Inhibition of DHODH is known to block clonal expansion and expression of effector molecules of activated T cells. However, this effect has been suggested to be caused by downstream impairment of oxidative phosphorylation rather than a lower rate of pyrimidine synthesis. In this study, we successfully inhibit the DHODH of T cells with no residual effect on oxidative phosphorylation and demonstrate a dose-dependent inhibition of proliferation of activated CD3+ T cells. This block is fully rescued when uridine is supplemented. Inhibition of DHODH does not alter expression of effector molecules but results in decreased intracellular levels of deoxypyrimidines without decreasing cell viability. Our results clearly demonstrate the DHODH and mitochondrial linked pyrimidine synthesis as an independent and important cytostatic regulator of activated T cells.

OriginalsprogEngelsk
Artikelnummer718863
TidsskriftFrontiers in Immunology
Vol/bind12
ISSN1664-3224
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
This study was supported by the Danish Council for Independent Research (Grant No. DFF-1331-00095B); Danish Cancer Society (Grant No. R72-A4396-13-S2); Nordea-Fonden, Novo Nordisk Foundation Challenge Programme NNF17OC0027812; The Danielsen Foundation; Dagmar Marshalls Fond; Else og Mogens Wedell-Wedellsborg Fond; AP M?ller Fonden; Den B?hmske Fond; KV foundation; Familien Erichsens Mindefond; Axel Muusfeldts Fond; Kong Christian den Tiendes Fond; Sven Wewers fond; Fabrikant Einar Willumsens Mindelegat; K?bmand Sven Hansen og Hustru Ina Hansens Fond; B?rnecancerfonden and T?mmermester J?rgen Holm og Hustru Elisa f. Hansens Mindelegat. PA received partial Ph.D. stipends from the Clinical Academic Group in Translational Hematology, part of Greater Copenhagen Health Science Partners, as well as from the Department of Immunology and Microbiology, University of Copenhagen, the Training Network for the Immunotherapy of Cancer funded by the EU (IMMUTRAIN; H2020 grant no.641549.

Publisher Copyright:
Copyright © 2021 Peeters, Aehnlich, Pizzella, Mølgaard, Seremet, Met, Rasmussen, thor Straten and Desler.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 287629507